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Epidemiologic data regarding the chemopreventive potential of nonsteroidal anti-inflammatory drugs (NSAIDs) against oral cancer
are sparse. We found a relative risk for oral cancer of 1.2 (95% CI, 1.0–1.6) among 169589 Danish NSAID users (X2 prescriptions),
with no apparent trends in subgroups. Our study provided no clear evidence that NSAIDs may protect against oral cancer.
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There is substantial experimental and epidemiological evidence
that aspirin and other nonsteroidal anti-inflammatory drugs
(NSAIDs) protect against colorectal adenomas and cancer (Baron,
2003; Ulrich et al, 2006). Epidemiologic studies have also
consistently pointed to inverse associations between NSAID use
and cancers of the stomach and oesophagus, whereas the results
are mixed for other cancer sites (Gonzalez-Perez et al, 2003).
Studies of animal models and human cancer cell lines have
indicated that the potential chemopreventive effect of NSAIDs
might extend to oral cancer (Goodin and Shiff, 2004; Wang, 2005),
and this year a large phase III prevention trial of COX-2 inhibitors
in patients with premalignant oral lesions (leukoplakia) is
scheduled to be launched (Nelson, 2006). Interestingly, only a
few epidemiological studies have provided data on the relationship
between NSAID use and oral cancer, and the data are conflicting
(Thun et al, 1993; Bosetti et al, 2003; Sørensen et al, 2003). This
paucity of epidemiologic data prompted us to examine the
incidence of oral cancer in a large cohort of NSAID users in
Denmark.
MATERIALS AND METHODS
The study was carried out within the population of North Jutland
County, Denmark (population approximately 490000 inhabitants),
during the study period 1 January 1991 to 31 December 2002. From
the files of the Danish Civil Registration System, established in
1968 (Frank, 2000), we identified all individuals in the county who
were 16 years or older during the study period and resident in the
county on 1 January 1991. We then excluded all individuals with a
history of cancer (except nonmelanoma skin cancer) before study
entry (1991 or age 16 years) by linkage to the Danish Cancer
Registry, which has had accurate and almost complete nationwide
ascertainment of cancer cases since 1943 (Storm et al, 1997). The
final study population comprised 442654 individuals.
The Danish National Health Service provides tax-supported
health care for all inhabitants and refunds part of patient
expenditures on a wide range of prescribed drugs, including non-
aspirin NSAIDs. In Denmark, non-aspirin NSAID can be obtained
only by prescription, except for low doses of ibuprofen which
account for approximately 14% of the total use (Sørensen et al,
2003). All health-related services are registered to individual
patients by use of a civil registry number assigned to all Danish
citizens, which encodes gender and date of birth. In North Jutland
County, pharmacy data are transferred to a research prescription
database, which was initiated in 1989 and covered all pharmacies
by 1991 (Gaist et al, 1997). The database holds key information
on all prescriptions for refundable drugs dispensed from
pharmacies in the county, including the type of drug prescribed
according to the ATC classification system (World Health
Organisation, 2001), date of dispensing at the pharmacy, and
the civil registry number. Use of the civil registry number allows
for the establishment of complete prescription histories for each
individual and secures valid linkage between population-based
registers.
Using the files of the prescription database and the cancer
registry, we identified 169589 individuals in the study population
who had redeemed two or more non-aspirin NSAID prescriptions
(ATC codes, M01A) during the study period, and who were free of
cancer at the date of their second prescription. For all individuals
in the study population, we also obtained information on
diagnoses of chronic obstructive pulmonary disease (COPD) from
the County Hospital Discharge Registry, a computerised database
containing information on all non-psychiatric hospital admissions
(since 1977) and outpatient visits (since 1995) in the county
(Skriver et al, 2005).
All individuals in the study population were followed from 1
January 1991 or age 16 years, whichever occurred latest, until
date of primary oral (mouth and tongue) cancer, other primary
cancer (except nonmelanoma skin cancer), death, migration, or 31
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study subjects was distributed according to use of NSAIDs in
exposed time (X2 prescriptions) (NSAID use) and unexposed
time (no prescriptions) (nonuse). Person time between first and
second NSAID prescription was excluded from the analyses to
reduce the possible association between NSAIDs and oral cancer
due to confounding by indication.
We calculated age- and gender-standardised incidence rates of
oral cancer by applying direct standardisation in gender-specific
5-year age groups to the age distribution in the entire study
population. Age- and gender-standardised incidence rate ratios
(IRR) were computed by dividing incidence rates of oral cancer for
NSAID users with incidence rates for nonusers. We categorised
NSAID use into two groups based on the number of redeemed
prescriptions (2–9 prescriptions, 10þ prescriptions). We further
performed a subanalysis according to a history of COPD (diagnosis
in the Hospital Discharge Registry during the period 1977–2002),
as an indirect control for smoking.
RESULTS
We identified 75 cases of oral cancer among NSAID users during
977627 person-years of follow-up (mean, 5.8 years) and 110 cases
among nonusers during 2521145 years of follow-up. The age-and
gender-standardised incidence rate was 6.1 per 100000 person-
years among NSAID users and 4.9 per 100000 person-years among
nonusers. The table presents the relative risk estimates for oral
cancer according to use of NSAIDs (Table 1). All IRR estimates
were close to one and stratification by number of prescriptions or
history of COPD revealed no apparent trends, although the IRR
estimates for COPD patients tended to be slightly lower than those
for the full cohort. The results did not change materially when
stratified according to gender (data not shown).
DISCUSSION
Our large population-based study based on registers with
essentially complete and unbiased ascertainment of prescriptions,
hospitalisations and outpatient visits for COPD, and cancer
outcomes provided no evidence that NSAID intake prevents oral
cancer. The incidence of oral cancer is increasing in many
countries, and the lack of efficient therapy and the considerable
associated morbidity and mortality make chemoprevention
attractive (Goodin and Shiff, 2004; Wang, 2005), particularly since
this might be targeted to high-risk individuals with leukoplakia or
other precursor lesions (Nelson, 2006). NSAIDs have shown
promise as chemopreventive agents for oral cancer in experimental
studies (Goodin and Shiff, 2004), but the available epidemiologic
data including the present analysis do not support a major
protective effect of NSAIDs against oral cancer.
Our findings may have been influenced by differences in NSAID
use according to important risk factors for oral cancer, notably
smoking and alcohol consumption. We were only able to indirectly
control for smoking by examining risk in a subset of patients
hospitalised with COPD, of whom the large majority can be
assumed to have been smokers. Our inability to adjust for actual
use of tobacco, alcohol consumption, and over-the-counter
purchase of low-dose ibuprofen and aspirin may have obscured
a preventive effect of NSAID use against oral cancer. However,
analyses of US health care utilisation data sets indicate that these
potential confounders have limited influence in studies of NSAID
use and various health outcomes (Schneeweiss et al, 2005). Also,
our finding of no substantial trends in IRRs over number of
NSAID prescriptions argues against a major protective effect of
NSAIDs on the development of oral cancer. The lack
of any clear effect even after stratification by history of COPD
similarly suggests no appreciable confounding by smoking,
although these analyses were based on small numbers. Further
epidemiological studies with large sample sizes and comprehensive
information on potential confounders may be warranted to
evaluate the chemopreventive potential of NSAIDs against oral
cancer.
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